Federal Judge Blocks Colorado Drug Affordability Board Price Cap on Amgen's Enbrel
A federal judge has blocked Colorado's Drug Affordability Board from implementing a price cap on Amgen's Enbrel, a blockbuster rheumatoid arthritis medication. The ruling prevents the state board from enforcing its pricing limit on the drug. The decision affects Colorado's ability to use its drug affordability review process to control costs for high-priced medications. This represents a significant setback for state efforts to directly regulate pharmaceutical pricing through affordability boards, with implications for how states can address drug costs in Medicaid programs.
The ruling limits states' ability to impose price caps on high-cost medications, potentially constraining Medicaid managed care organizations' options for controlling pharmacy costs and challenging state-level drug affordability initiatives that MCOs rely on to manage specialty drug spending.
Pharmacy · Managed Care
You might also like